Archive 2006 |
December 13, 2006 GPC Biotech Responds to Arbitration Claim by Spectrum Pharmaceuticals |
December 11, 2006 GPC Biotech Presents Preliminary Clinical Data on Anticancer Monoclonal Antibody 1D09C3 at ASH |
November 22, 2006 GPC Biotech to Present at Two Upcoming Conferences: Deutsches Eigenkapitalforum in Frankfurt and Piper Jaffray 18th Annual Health Care Conference in New York |
November 9, 2006 GPC Biotech Reports Financial Results for Third Quarter and First Nine Months of 2006 |
November 2, 2006 GPC Biotech Meeting and Conference Call on Results for the Third Quarter and First Nine Months of 2006 Scheduled for November 9th |
October 30, 2006 GPC Biotech to Present at Two Upcoming Conferences: Rodman & Renshaw Annual Healthcare Conference in New York and Cowen & Co. Global Health Care Conference in London |
October 12, 2006 GPC Biotech to Present at BIO Investor Forum in San Francisco |
September 25, 2006 GPC Biotech to Present at UBS Global Life Sciences Conference in New York City |
September 25, 2006 GPC Biotech Schedules Conference Call for Today, Monday, September 25 to Discuss Positive Results from the Satraplatin Pivotal Phase 3 Trial |
September 24, 2006 GPC Biotech and Pharmion Announce Positive Results from the Satraplatin Pivotal Phase 3 Trial and Achievement of the Progression-Free Survival Endpoint |
August 8, 2006 GPC Biotech Reports Financial Results for Second Quarter and First Six Months of 2006 |
August 2, 2006 GPC Biotech Initiates Phase 2 Randomized Trial Evaluating Satraplatin plus Tarceva® in Patients with Advanced Non-Small Cell Lung Cancer |
August 1, 2006 GPC Biotech Schedules Conference Call on August 8th to Discuss First Half 2006 Financial Results |
July 12, 2006 GPC Biotech Submits Non-Clinical Section of Rolling NDA for Lead Oncology Drug Candidate Satraplatin |
June 8, 2006 Independent Data Monitoring Board Recommends that Satraplatin Phase 3 Trial Continue as Planned |
June 6, 2006 GPC Biotech Presents New Satraplatin Clinical Data from Two Pharmacokinetics Studies at ASCO |
June 2, 2006 GPC Biotech to Present at Three Conferences in the U.S. in June |
May 17, 2006 Independent Data Monitoring Board Recommends Expedited Interim Analysis of Overall Survival Data for Satraplatin Phase 3 Trial |
May 16, 2006 GPC Biotech Announces Start of Phase 1 Trial Evaluating Satraplatin plus Xeloda® in Patients with Advanced Solid Tumors |
Mai 8, 2006 GPC Biotech to Present at Rodman & Renshaw 3rd Annual Global Healthcare Conference |
May 4, 2006 GPC Biotech Reports Financial Results for First Quarter of 2006 |
April 27, 2006 GPC Biotech Schedules Conference Call on May 4th to Discuss First Quarter 2006 Financial Results |
April 25, 2006 Independent Data Monitoring Board Recommends that GPC Biotech Continue Satraplatin Phase 3 Trial as Planned |
April 19, 2006 GPC Biotech Expands Drug Development and Commercialization Management Teams with Three New Senior Executives |
April 3, 2006 GPC Biotech Presents New Satraplatin Pre-clinical Data at AACR |
March 15, 2006 GPC Biotech Reports Financial Results for Fiscal Year 2005 |
March 8, 2006 GPC Biotech Meeting and Conference Call on Business Results for the Fiscal Year 2005 Scheduled for March 15 |
February 28, 2006 GPC Biotech to Present at Two Upcoming Conferences in the U.S. |
February 27, 2006 GPC Biotech Presents New Satraplatin Clinical Data from Pharmacokinetics Study at ASCO Prostate Cancer Symposium |
February 24, 2006 GPC Biotech Raises € 36.2 Million in Private Placement with SAP Co-Founder Dietmar Hopp |
February 14, 2006 European Regulatory Committee Recommends Orphan Drug Status for GPC Biotech’s Anticancer Monoclonal Antibody 1D09C3 for Multiple Myeloma |
February 7, 2006 GPC Biotech to Present at Eighth Annual BIO CEO & Investor Conference in New York City |
January 27, 2006 Orphan Drug Designation Granted by European Commission for Anticancer Monoclonal Antibody 1D09C3 for Chronic Lymphocytic Leukemia |
